Comparing infusion timing for lung cancer immunotherapy before surgery
Part of Cancer, Lungs & breathing clinical trials.
This trial tests whether the timing of immunotherapy infusion before surgery improves how well the tumor responds in people with stage II to III non-small cell lung cancer. It combines immunotherapy with standard chemotherapy to shrink the tumor before it is removed.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have stage II or III non-small cell lung cancer that can be removed with surgery.
- You have not had prior chemotherapy, immunotherapy, or other cancer treatment for this lung cancer.
- Your general health is good enough for surgery (ECOG score 0 or 1).
- You do not have specific gene mutations (EGFR, ALK/ROS1) or active brain metastases.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if receiving immunotherapy before surgery works better than getting it after surgery for people with stage II to IIIB non-small cell lung cancer. The goal is to see which timing helps prevent the cancer from coming back.
This study compares three different schedules for giving immunotherapy (a cancer-fighting drug) to patients with early-stage non-small cell lung cancer who are having surgery. The goal is to find out which timing—before surgery, after surgery, or both—works best to prevent cancer from coming back.
This trial tests giving toripalimab plus another treatment (JS004) together with standard chemotherapy before lung surgery for stage IIIB–IIIC non-small cell lung cancer. It may help shrink the tumor and make surgery more effective, and it compares different treatment combinations.
This trial tests a combination of radiation therapy, an immunotherapy drug called toripalimab, and chemotherapy given before surgery for stage II-III non-small cell lung cancer. The goal is to shrink the tumor before removal and improve survival outcomes.
This trial studies a comprehensive treatment approach for lung cancer that combines immunotherapy given before surgery with standard surgery. It aims to understand how well this approach works by analyzing your medical data and samples.
This trial tests a combination of radiation, immunotherapy (QL1706), and chemotherapy given before surgery for non-small-cell lung cancer that can be removed. It aims to see if this approach can shrink the tumor and improve outcomes.
Hear when a new Resectable Stage II-III Non-Small Cell Lung Cancer (NSCLC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.